With support from the Department of Defense Breast Cancer Research Program (BCRP), Dr. George Prendergast established IDO as a target for cancer treatment and identified several novel inhibitors of IDO, some of which are currently in clinical trials for recurrent or refractory solid tumors, including breast cancer.